NAD+/NADH metabolism and NAD+-dependent enzymes in cell death and ischemic brain injury: Current advances and therapeutic implications

Current Medicinal Chemistry

Volumn 22, Issue 10, 2015, Pages 1239-1247

  Ma, Yingxin ^a   Nie, Hui ^a   Chen, Heyu ^a   Li, Jiefu ^a   Hong, Yunyi ^a   Wang, Ban ^a   Wang, Caixia ^a   Zhang, Jie ^a   Cao, Wei ^a   Zhang, Mingchao ^a   Xu, Yongning ^a   Ding, Xianting ^a   Yin, Shan Kai ^a   Qu, Xinkai ^b   Ying, Weihai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI CHEST HOSPITAL   (China)

Author keywords

CD38; Cell death; Ischemic brain injury; NAD+; Poly(ADP ribose) polymerase; Sirtuins

Indexed keywords

CD38 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTUIN; SIRTUIN 1;

APOPTOSIS; ARTICLE; AUTOPHAGY; BRAIN ISCHEMIA; ENERGY METABOLISM; HEAD INJURY; INFLAMMATION; MITOCHONDRION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; TRAUMATIC BRAIN INJURY; ANIMAL; BRAIN INJURIES; CELL DEATH; HUMAN; METABOLISM;

ANIMALS; ANTIGENS, CD38; BRAIN INJURIES; BRAIN ISCHEMIA; CELL DEATH; HUMANS; NAD; POLY(ADP-RIBOSE) POLYMERASES; SIRTUINS;

EID: 84931261503     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150209154420     Document Type: Article

References (108)

1. Ying W. NAD+ and NADH in cellular functions and cell death. Front. Biosci., 2006, 11, 3129-3148.
2. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid. Redox. Signal., 2008, 10 (2), 179-206.
3. Xia W.; Wang, Z.; Wang, Q.; Han, J.; Zhao, C.; Hong, Y.; Zeng, L.; Tang, L.; Ying, W. Roles of NAD+ /NADH and NADP+ /NADPH in cell death. Curr. Pharm. Des., 2009, 15 (1), 12-19.
4. Ying W.; Wei, G.; Wang, D.; Wang, Q.; Tang, X.; Shi, J.; Zhang, P.; Lu, H. Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia. Front. Biosci., 2007, 12, 2728-2734.
5. Matsuura S.; Egi, Y.; Yuki, S.; Horikawa, T.; Satoh, H.; Akira, T. MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model. Brain Res., 2011, 1410, 122-131.
6. Ying W.; Garnier, P.; Swanson, R.A. NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. Biochem. Biophys. Res. Commun., 2003, 308 (4), 809-813.
7. C.C.; Ying, W.; Swanson, R.A. Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J. Biol. Chem., 2004, 279 (18), 18895-18902.
8. Wang S.; Xing, Z.; Vosler, P.S.; Yin, H.; Li, W.; Zhang, F.; Signore, A.P.; Stetler, R.A.; Gao, Y.; Chen, J. Cellular NAD replenishment confers marked neuroprotection against ischemic cell death: role of enhanced DNA repair. Stroke, 2008, 39 (9), 2587-2595.
9. Cai A.L.; Zipfel, G.J.; Sheline, C.T. Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway. Eur. J. Neurosci., 2006, 24 (8), 2169-2176.
10. Alano C.C.; Garnier, P.; Ying, W.; Higashi, Y.; Kauppinen, T.M.; Swanson, R.A. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J. Neurosci., 2010, 30 (8), 2967-2978.
11. Wang S.; Song, P.; Zou, M.H. Inhibition of AMP-activated protein kinase alpha (AMPKalpha) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. J. Biol. Chem., 2012, 287 (11), 8001-8012.
12. Hong Y.; Nie, H.; Wu, D.; Wei, X.; Ding, X.; Ying, W. NAD+ treatment prevents rotenone-induced apoptosis and necrosis of differentiated PC12 cells. Neurosci. Lett., 2014, 560, 46-50.
13. Hong Y S.J., Xia W, Ying W. NAD+ treatment can block rotenoneinduced nuclear apoptotic changes of PC12 cells. FASEB J., 2010 (2010' Experimental Biology Meeting Abstracts.), 965.966.
14. Pittelli M.; Felici, R.; Pitozzi, V.; Giovannelli, L.; Bigagli, E.; Cialdai, F.; Romano, G.; Moroni, F.; Chiarugi, A. Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Mol. Pharmacol., 2011, 80 (6), 1136-1146.
15. Zheng C.; Han, J.; Xia, W.; Shi, S.; Liu, J.; Ying, W. NAD+ administration decreases ischemic brain damage partially by blocking autophagy in a mouse model of brain ischemia. Neurosci. Lett., 2012, 512(2), 67-71.
16. Bruzzone S.; Guida, L.; Zocchi, E.; Franco, L.; De Flora, A. Connexin 43 hemi channels mediate Ca2+-regulated transmembrane NAD+ fluxes in intact cells. FASEB J., 2001, 15 (1), 10-12.
17. Chen, H.; Wang, Y.; Zhang, J.; Ma, Y.; Wang, C.; Zhou, Y.; Gu, H.; Ying, W. NAD+-Carrying Mesoporous Silica Nanoparticles Can Prevent Oxidative Stress-Induced Energy Failures of Both Rodent Astrocytes and PC12 Cells. PLoS One, 2013, 8 (9), e74100.
18. Pillai J.B.; Gupta, M.; Rajamohan, S.B.; Lang, R.; Raman, J.; Gupta, M.P. Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol., 2006, 291 (4), H1545-1553.
19. Hsu C.P.; Oka, S.; Shao, D.; Hariharan, N.; Sadoshima, J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ. Res., 2009, 105 (5), 481-491.
20. Eliasson M.J.; Sampei, K.; Mandir, A.S.; Hurn, P.D.; Traystman, R.J.; Bao, J.; Pieper, A.; Wang, Z.Q.; Dawson, T.M.; Snyder, S.H.; Dawson, V.L. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med., 1997, 3 (10), 1089-1095.
21. Endres M.; Wang, Z.Q.; Namura, S.; Waeber, C.; Moskowitz, M.A. Ischemic brain injury is mediated by the activation of poly(ADPribose) polymerase. J. Cereb. Blood Flow Metab., 1997, 17 (11), 1143-1151.
22. Siegel C.S.; McCullough, L.D. NAD+ and nicotinamide: sex differences in cerebral ischemia. Neuroscience, 2013, 237, 223-231.
23. Shimizu T.; Macey, T.A.; Quillinan, N.; Klawitter, J.; Perraud, A.L.; Traystman, R.J.; Herson, P.S. Androgen and PARP-1 regulation of TRPM2 channels after ischemic injury. J. Cereb. Blood Flow Metab., 2013, 33(10), 1549-1555.
24. Won S.J.; Choi, B.Y.; Yoo, B.H.; Sohn, M.; Ying, W.; Swanson, R.; Suh, S.W. Prevention of traumatic brain injury-induced neuron death by intranasal delivery of NAD+. J. Neurotrauma, 2012, 29 (7), 1401-1409.
25. Xia W.; Han, J.; Huang, G.; Ying, W. Inflammation in ischaemic brain injury: current advances and future perspectives. Clin. Exp. Pharmacol. Physiol., 2010, 37 (2), 253-258.
26. Woodcock T.; Morganti-Kossmann, M.C. The role of markers of inflammation in traumatic brain injury. Front. Neurol., 2013, 4, 18.
27. Kauppinen T.M.; Gan, L.; Swanson, R.A. Poly(ADP-ribose) polymerase-1-induced NAD+ depletion promotes nuclear factorkappaB transcriptional activity by preventing p65 de-acetylation. Biochim. Biophys. Acta., 2013, 1833 (8), 1985-1991.
28. Sheng C.; Chen, H.; Wang, B.; Liu, T.; Hong, Y.; Shao, J.; He, X.; Ma, Y.; Nie, H.; Liu, N.; Xia, W.; Ying, W. NAD+ administration significantly attenuates synchrotron radiation X-ray-induced DNA damage and structural alterations of rodent testes. Int. J. Physiol. Pathophysiol. Pharmacol., 2012, 4 (1), 1-9.
29. Wang B.; Ma, Y.; Kong, X.; Ding, X.; Gu, H.; Chu, T.; Ying, W. NAD+ administration decreases doxorubicin-induced liver damage of mice by enhancing antioxidation capacity and decreasing DNA damage. Chem. Biol. Interact., 2014, 212, 65-71.
30. Ying W. NAD+ and NADH in brain functions, brain diseases and brain aging. Front. Biosci., 2007, 12, 1863-1888.
31. Lu H.; Burns, D.; Garnier, P.; Wei, G.; Zhu, K.; Ying, W. P2X7 receptors mediate NADH transport across the plasma membranes of astrocytes. Biochem. Biophys. Res. Commun., 2007, 362 (4), 946-950.
32. Zhu K.; Swanson, R.A.; Ying, W. NADH can enter into astrocytes and block poly(ADP-ribose) polymerase-1-mediated astrocyte death. Neuroreport, 2005, 16 (11), 1209-1212.
33. Ma Y.; Chen, H.; Xia, W.; Ying, W. Oxidative stress and PARP activation mediate the NADH-induced decrease in glioma cell survival. Int. J. Physiol. Pathophysiol. Pharmacol., 2011, 3 (1), 21-28.
34. Stryer L. Biochemistry. W.H. Freeman and Company: New York, 1995.
35. Thornburg J.M.; Nelson, K.K.; Clem, B.F.; Lane, A.N.; Arumugam, S.; Simmons, A.; Eaton, J.W.; Telang, S.; Chesney, J. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res., 2008, 10 (5), R84.
36. Pardo B.; Contreras, L.; Satrustegui, J. Synthesis of Glial Glutamate and Glutamine in Young Mice Requires Aspartate Provided by the Neuronal Mitochondrial Aspartate-Glutamate Carrier Aralar/AGC1. Front. Endocrinol. (Lausanne), 2013, 4, 149.
37. Rubi B.; del Arco, A.; Bartley, C.; Satrustegui, J.; Maechler, P. The malate-aspartate NADH shuttle member Aralar1 determines glucose metabolic fate, mitochondrial activity, and insulin secretion in beta cells. J. Biol. Chem., 2004, 279 (53), 55659-55666.
38. Ying W.; Xiong, Z.G. Oxidative stress and NAD+ in ischemic brain injury: current advances and future perspectives. Curr. Med. Chem., 2010, 17 (20), 2152-2158.
39. Bickler P.E.; Fahlman, C.S.; Gray, J.; McKleroy, W. Inositol 1,4,5-triphosphate receptors and NAD(P)H mediate Ca2+ signaling required for hypoxic preconditioning of hippocampal neurons. Neuroscience, 2009, 160 (1), 51-60.
40. D'Amours D.; Desnoyers, S.; D'Silva, I.; Poirier, G.G. Poly(ADPribosyl) ation reactions in the regulation of nuclear functions. Biochem. J., 1999, 342 ( Pt 2), 249-268.
41. Vandenabeele P.; Galluzzi, L.; Vanden Berghe, T.; Kroemer, G. Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat. Rev. Mol. Cell Biol., 2010, 11 (10), 700-714.
42. Cauwels A.; Janssen, B.; Waeytens, A.; Cuvelier, C.; Brouckaert, P. Caspase inhibition causes hyperacute tumor necrosis factorinduced shock via oxidative stress and phospholipase A2. Nat. Immunol., 2003, 4 (4), 387-393.
43. Sosna J.; Voigt, S.; Mathieu, S.; Lange, A.; Thon, L.; Davarnia, P.; Herdegen, T.; Linkermann, A.; Rittger, A.; Chan, F.K.; Kabelitz, D.; Schutze, S.; Adam, D. TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death. Cell Mol. Life Sci., 2014, 71(2) 331-348.
44. Boulares A.H.; Zoltoski, A.J.; Contreras, F.J.; Yakovlev, A.G.; Yoshihara, K.; Smulson, M.E. Regulation of DNAS1L3 endonuclease activity by poly(ADP-ribosyl)ation during etoposideinduced apoptosis. Role of poly(ADP-ribose) polymerase-1 cleavage in endonuclease activation. J. Biol. Chem., 2002, 277 (1), 372-378.
45. Boulares A.H.; Zoltoski, A.J.; Sherif, Z.A.; Yakovlev, A.G.; Smulson, M.E. The Poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells. Cancer Res., 2002, 62 (15), 4439-4444.
46. Wyrsch P.; Blenn, C.; Bader, J.; Althaus, F.R. Cell death and autophagy under oxidative stress: roles of poly(ADP-Ribose) polymerases and Ca2+. Mol. Cell Biol., 2012, 32 (17), 3541-3553.
47. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev., 2000, 14 (9), 1021-1026.
48. Dali-Youcef N.; Lagouge, M.; Froelich, S.; Koehl, C.; Schoonjans, K.; Auwerx, J. Sirtuins: The 'magnificent seven', function, metabolism and longevity. Ann. Med., 2007, 39 (5), 335-345.
49. Kim E.J.; Kho, J.H.; Kang, M.R.; Um, S.J. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell, 2007, 28 (2), 277-290.
50. Sundaresan N.R.; Pillai, V.B.; Gupta, M.P. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J. Mol. Cell Cardiol., 2011, 51 (4), 614-618.
51. Kolthur-Seetharam U.; Dantzer, F.; McBurney, M.W.; de Murcia, G.; Sassone-Corsi, P. Control of AIF-mediated Cell Death by the Functional Interplay of SIRT1 and PARP-1 in Response to DNA Damage. Cell Cycle, 2006, 5 (8), 873-877.
52. Winnik S.; Stein, S.; Matter, C.M. SIRT1-an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr. Vasc. Pharmacol., 2012, 10 (6), 693-696.
53. Yeung F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J., 2004, 23 (12), 2369-2380.
54. Outeiro TF K.E., Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science, 2007, 317, 516-519.
55. Luthi-Carter R.; Taylor, D.M.; Pallos, J.; Lambert, E.; Amore, A.; Parker, A.; Moffitt, H.; Smith, D.L.; Runne, H.; Gokce, O.; Kuhn, A.; Xiang, Z.; Maxwell, M.M.; Reeves, S.A.; Bates, G.P.; Neri, C.; Thompson, L.M.; Marsh, J.L.; Kazantsev, A.G. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl. Acad. Sci. U. S. A., 2010, 107 (17), 7927-7932.
56. Li Y.; Matsumori, H.; Nakayama, Y.; Osaki, M.; Kojima, H.; Kurimasa, A.; Ito, H.; Mori, S.; Katoh, M.; Oshimura, M.; Inoue, T. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells, 2011, 16 (1), 34-45.
57. He X.; Nie, H.; Hong, Y.; Sheng, C.; Xia, W.; Ying, W. SIRT2 activity is required for the survival of C6 glioma cells. Biochem. Biophys. Res. Commun., 2012, 417 (1), 468-472.
58. Wang F.; Nguyen, M.; Qin, F.X.; Tong, Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell, 2007, 6 (4), 505-514.
59. Outeiro T.F.; Kontopoulos, E.; Altmann, S.M.; Kufareva, I.; Strathearn, K.E.; Amore, A.M.; Volk, C.B.; Maxwell, M.M.; Rochet, J.C.; McLean, P.J.; Young, A.B.; Abagyan, R.; Feany, M.B.; Hyman, B.T.; Kazantsev, A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science, 2007, 317 (5837), 516-519.
60. Narayan N.; Lee, I.H.; Borenstein, R.; Sun, J.; Wong, R.; Tong, G.; Fergusson, M.M.; Liu, J.; Rovira, II; Cheng, H.L.; Wang, G.; Gucek, M.; Lombard, D.; Alt, F.W.; Sack, M.N.; Murphy, E.; Cao, L.; Finkel, T. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature, 2012.
61. Nie H.; Chen, H.; Han, J.; Hong, Y.; Ma, Y.; Xia, W.; Ying, W. Silencing of SIRT2 induces cell death and a decrease in the intracellular ATP level of PC12 cells. Int. J. Physiol. Pathophysiol. Pharmacol., 2011, 3 (1), 65-70.
62. Nie H.; Hong, Y.; Lu, X.; Zhang, J.; Chen, H.; Li, Y.; Ma, Y.; Ying, W. SIRT2 mediates oxidative stress-induced apoptosis of differentiated PC12 cells. Neuroreport, 2014, 25 (11), 838-842.
63. Kim M.J.; Kim, D.W.; Park, J.H.; Kim, S.J.; Lee, C.H.; Yong, J.I.; Ryu, E.J.; Cho, S.B.; Yeo, H.J.; Hyeon, J.; Cho, S.W.; Kim, D.S.; Son, O.; Park, J.; Han, K.H.; Cho, Y.S.; Eum, W.S.; Choi, S.Y. PEP-1-SIRT2 inhibits inflammatory response and oxidative stressinduced cell death via expression of antioxidant enzymes in murine macrophages. Free Radic. Biol. Med., 2013, 63, 432-445.
64. Li Y.; Nie, H.; Wu, D.; Zhang, J.; Wei, X.; Ying, W. Poly(ADPribose) polymerase mediates both cell death and ATP decreases in SIRT2 inhibitor AGK2-treated microglial BV2 cells. Neurosci. Lett. 2013, 544, 36-40.
65. Huang J.Y.; Hirschey, M.D.; Shimazu, T.; Ho, L.; Verdin, E. Mitochondrial sirtuins. Biochim. Biophys. Acta., 1804 (8), 1645-1651.
66. Yang H.; Yang, T.; Baur, J.A.; Perez, E.; Matsui, T.; Carmona, J.J.; Lamming, D.W.; Souza-Pinto, N.C.; Bohr, V.A.; Rosenzweig, A.; de Cabo, R.; Sauve, A.A.; Sinclair, D.A. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell, 2007, 130 (6), 1095-1107.
67. Sundaresan N.R.; Gupta, M.; Kim, G.; Rajamohan, S.B.; Isbatan, A.; Gupta, M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest., 2009, 119 (9), 2758-2771.
68. Kim S.H.; Lu, H.F.; Alano, C.C. Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One, 2011, 6 (3), e14731.
69. Pellegrini L.; Pucci, B.; Villanova, L.; Marino, M.L.; Marfe, G.; Sansone, L.; Vernucci, E.; Bellizzi, D.; Reali, V.; Fini, M.; Russo, M.A.; Tafani, M. SIRT3 protects from hypoxia and staurosporinemediated cell death by maintaining mitochondrial membrane potential and intracellular pH. Cell Death Differ., 2012, 19 (11), 1815-1825.
70. Cheng Y.; Ren, X.; Gowda, A.S.; Shan, Y.; Zhang, L.; Yuan, Y.S.; Patel, R.; Wu, H.; Huber-Keener, K.; Yang, J.W.; Liu, D.; Spratt, T.E.; Yang, J.M. Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress. Cell Death Dis., 2013, 4, e731.
71. Pfister J.A.; Ma, C.; Morrison, B.E.; D'Mello, S.R. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One, 2008, 3 (12), e4090.
72. Khongkow M.; Olmos, Y.; Gong, C.; Gomes, A.R.; Monteiro, L.J.; Yague, E.; Cavaco, T.B.; Khongkow, P.; Man, E.P.; Laohasinnarong, S.; Koo, C.Y.; Harada-Shoji, N.; Tsang, J.W.; Coombes, R.C.; Schwer, B.; Khoo, U.S.; Lam, E.W. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis, 2013, 34 (7), 1476-1486.
73. Van Meter M.; Mao, Z.; Gorbunova, V.; Seluanov, A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle, 2011, 10 (18), 3153-3158.
74. Vakhrusheva O.; Smolka, C.; Gajawada, P.; Kostin, S.; Boettger, T.; Kubin, T.; Braun, T.; Bober, E. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ. Res., 2008, 102 (6), 703-710.
75. Ford E.; Voit, R.; Liszt, G.; Magin, C.; Grummt, I.; Guarente, L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev., 2006, 20 (9), 1075-1080.
76. Malavasi F.; Deaglio, S.; Funaro, A.; Ferrero, E.; Horenstein, A.L.; Ortolan, E.; Vaisitti, T.; Aydin, S. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev., 2008, 88 (3), 841-886.
77. Malavasi F.; Deaglio, S.; Damle, R.; Cutrona, G.; Ferrarini, M.; Chiorazzi, N. CD38 and chronic lymphocytic leukemia: A decade later. Blood, 2011, 118 (13), 3470-3478.
78. Lee H.C. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 317-345.
79. Aksoy P.; White, T.A.; Thompson, M.; Chini, E.N. Regulation of intracellular levels of NAD: A novel role for CD38. Biochem. Biophys. Res. Commun., 2006, 345 (4), 1386-1392.
80. Aksoy P.; Escande, C.; White, T.A.; Thompson, M.; Soares, S.; Benech, J.C.; Chini, E.N. Regulation of SIRT 1 mediated NAD dependent deacetylation: A novel role for the multifunctional enzyme CD38. Biochem. Biophys. Res. Commun., 2006, 349 (1), 353-359.
81. Partida-Sanchez S.; Cockayne, D.A.; Monard, S.; Jacobson, E.L.; Oppenheimer, N.; Garvy, B.; Kusser, K.; Goodrich, S.; Howard, M.; Harmsen, A.; Randall, T.D.; Lund, F.E. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat. Med., 2001, 7 (11), 1209-1216.
82. Xiong J.; Xia, M.; Yi, F.; Abais, J.M.; Li, N.; Boini, K.M.; Li, P.L. Regulation of renin release via cyclic ADP-ribose-mediated signaling: evidence from mice lacking CD38 gene. Cell Physiol. Biochem., 2013, 31 (1), 44-55.
83. Bruzzone S.; Verderio, C.; Schenk, U.; Fedele, E.; Zocchi, E.; Matteoli, M.; De Flora, A. Glutamate-mediated overexpression of CD38 in astrocytes cultured with neurones. J. of Neurochem., 2004, 89 (1), 264-272.
84. Mayo L.; Jacob-Hirsch, J.; Amariglio, N.; Rechavi, G.; Moutin, M.J.; Lund, F.E.; Stein, R. Dual role of CD38 in microglial activation and activation-induced cell death. J. Immunol., 2008, 181 (1), 92-103.
85. Banerjee S.; Walseth, T.F.; Borgmann, K.; Wu, L.; Bidasee, K.R.; Kannan, M.S.; Ghorpade, A. CD38/cyclic ADP-ribose regulates astrocyte calcium signaling: Implications for neuroinflammation and HIV-1-associated dementia. J. of Neuroimmune Pharmacol., 2008, 3 (3), 154-164.
86. Ma Y.; Jiang, J.; Wang, L.; Nie, H.; Xia, W.; Liu, J.; Ying, W. CD38 is a key enzyme for the survival of mouse microglial BV2 cells. Biochem. Biophys. Res. Commun., 2012, 418 (4), 714-719.
87. Ma Y.; Cao, W.; Wang, L.; Jiang, J.; Nie, H.; Wang, B.; Wei, X.; Ying, W. Basal CD38/cyclic ADP-ribose-dependent signaling mediates ATP release and survival of microglia by modulating connexin 43 hemichannels. Glia, 2014, 62 (6), 943-955.
88. Goto S.; Xue, R.; Sugo, N.; Sawada, M.; Blizzard, K.K.; Poitras, M.F.; Johns, D.C.; Dawson, T.M.; Dawson, V.L.; Crain, B.J.; Traystman, R.J.; Mori, S.; Hurn, P.D. Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery. Stroke, 2002, 33 (4), 1101-1106.
89. Love S.; Barber, R.; Wilcock, G.K. Neuronal accumulation of poly(ADP-ribose) after brain ischaemia. Neuropathol. Appl. Neurobiol., 1999, 25 (2), 98-103.
90. Teng F.; Beray-Berthat, V.; Coqueran, B.; Lesbats, C.; Kuntz, M.; Palmier, B.; Garraud, M.; Bedfert, C.; Slane, N.; Berezowski, V.; Szeremeta, F.; Hachani, J.; Scherman, D.; Plotkine, M.; Doan, B.T.; Marchand-Leroux, C.; Margaill, I. Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice. Exp. Neurol., 2013, 248, 416-428.
91. Nagayama T.; Simon, R.P.; Chen, D.; Henshall, D.C.; Pei, W.; Stetler, R.A.; Chen, J. Activation of poly(ADP-ribose) polymerase in the rat hippocampus may contribute to cellular recovery following sublethal transient global ischemia. J. Neurochem., 2000, 74 (4), 1636-1645.
92. Yang Y.; Candelario-Jalil, E.; Thompson, J.F.; Cuadrado, E.; Estrada, E.Y.; Rosell, A.; Montaner, J.; Rosenberg, G.A. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J. Neurochem., 2010,112 (1), 134-149.
93. Yuan M.; Siegel, C.; Zeng, Z.; Li, J.; Liu, F.; McCullough, L.D. Sex differences in the response to activation of the poly (ADPribose) polymerase pathway after experimental stroke. Exp. Neurol., 2009, 217 (1), 210-218.
94. McCullough L.D.; Zeng, Z.; Blizzard, K.K.; Debchoudhury, I.; Hurn, P.D. Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J. Cereb. Blood Flow Metab., 2005, 25 (4), 502-512.
95. Fonfria E.; Marshall, I.C.; Benham, C.D.; Boyfield, I.; Brown, J.D.; Hill, K.; Hughes, J.P.; Skaper, S.D.; McNulty, S. TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase. Br. J. Pharmacol., 2004, 143 (1), 186-192.
96. Yang K.T.; Chang, W.L.; Yang, P.C.; Chien, C.L.; Lai, M.S.; Su, M.J.; Wu, M.L. Activation of the transient receptor potential M2 channel and poly(ADP-ribose) polymerase is involved in oxidative stress-induced cardiomyocyte death. Cell Death Differ., 2006, 13 (10), 1815-1826.
97. Sheng C.; Chen, H.; Wang, B.; Wang, C.; Lin, L.; Li, Y.; Ying, W. Poly (ADP-ribose) Polymerase Activation Mediates Synchrotron Radiation X-Ray-Induced Damage of Rodent Testes by Exacerbating DNA Damage and Apoptotic Changes. Int. J. Radiat. Biol., 2014 (0), 1-18.
98. Datta S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 1997, 91 (2), 231-241.
99. Brunet A.; Datta, S.R.; Greenberg, M.E. Transcription-dependent and-independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol., 2001, 11 (3), 297-305.
100. Luo H.R.; Hattori, H.; Hossain, M.A.; Hester, L.; Huang, Y.; Lee-Kwon, W.; Donowitz, M.; Nagata, E.; Snyder, S.H. Akt as a mediator of cell death. Proc. Natl. Acad. Sci. U. S. A., 2003, 100 (20), 11712-11717.
101. Ditsworth D.; Zong, W.X.; Thompson, C.B. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the proinflammatory mediator HMGB1 from the nucleus. J. Biol. Chem., 2007, 282 (24), 17845-17854.
102. Hassa P.O.; Hottiger, M.O. A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation. Biol. Chem., 1999, 380 (7-8), 953-959.
103. Kameoka M.; Ota, K.; Tetsuka, T.; Tanaka, Y.; Itaya, A.; Okamoto, T.; Yoshihara, K. Evidence for regulation of NF-kappaB by poly(ADP-ribose) polymerase. Biochem. J., 2000, 346 Pt 3, 641-649.
104. Hernandez-Jimenez M.; Hurtado, O.; Cuartero, M.I.; Ballesteros, I.; Moraga, A.; Pradillo, J.M.; McBurney, M.W.; Lizasoain, I.; Moro, M.A. Silent Information Regulator 1 Protects the Brain Against Cerebral Ischemic Damage. Stroke, 2013, 44 (8), 2333-2337.
105. Lee J.M.; Zipfel, G.J.; Choi, D.W. The changing landscape of ischaemic brain injury mechanisms. Nature, 1999, 399 (6738 Suppl), A7-14.
106. Choe C.U.; Lardong, K.; Gelderblom, M.; Ludewig, P.; Leypoldt, F.; Koch-Nolte, F.; Gerloff, C.; Magnus, T. CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral ischemia. PLoS One, 2011, 6 (5), e19046.
107. Levy A.; Bercovich-Kinori, A.; Alexandrovich, A.G.; Tsenter, J.; Trembovler, V.; Lund, F.E.; Shohami, E.; Stein, R.; Mayo, L. CD38 facilitates recovery from traumatic brain injury. J. Neurotrauma, 2009, 26 (9), 1521-1533.
108. Bramlett H.M.; Dietrich, W.D. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J. Cereb. Blood Flow Metab., 2004, 24 (2), 133-150.